ClinicalTrials.gg
CompletedNCT03414814Updated Feb 11, 2025Results posted

Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation

A Phase 2 interventional study of Osimertinib 80 MG [Tagrisso] in Locally Advanced or Metastatic NSCLC, sponsored by Seoul National University Hospital. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-02-11.

Sponsored by Seoul National University Hospital · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung — 20 open to participants now, 43 under way, 8 of them phase 3. osimertinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
81st of 90
15 · median 51
Started
2018
with 12 others
Phase 2
46 of 90
12 open now
Registered
31st of 90
by date

Among the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, this one is the 81st largest by enrollment, is one of 13 that started in 2018, is one of 46 in phase 2, and was the 31st registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

20 of the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung are open now, in 7 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About osimertinib

osimertinib: first FDA approval 2015 (TAGRISSO), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a single-arm, non-randomized multicentre phase 2 study in NSCLC patients with EGFR exon 20 insertion mutation, whose disease has progressed on standard chemotherapy.

Read the detailed description

EGFR exon 20 insertion-mutant NSCLCs are generally resistant to 1st-generation EGFR tyrosine kinase inhibitors (TKIs) as well as 2nd-generation EGFR TKIs (overall response rates of 0-8.7%). Osimertinib is an oral, potent, irreversible EGFR-TKI selective for sensitizing EGFR and EGFR T790M resistance mutations with a significant selectivity margin against wild-type EGFR. Osimertinib is potent with a wide therapeutic window in Ba/F3 cells with EGFR exon 20 insertion mutations. Therefore, this study will be performed to investigate the efficacy of osimertinib in NSCLC patients with EGFR exon 20 insertion mutation

03

Conditions studied

  • Locally Advanced or Metastatic NSCLC

Keywords

  • NSCLC
  • Osimertinib
  • EGFR exon 20 insertion mutation
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of prior to any study specific procedures
  2. Male or female must be > 19 years of age.
  3. Locally advanced or NSCLC, not amenable to curative surgery or radiotherapy with local confirmation of the presence of the EGFR exon 20 insertion mutation
  4. Disease progression while on standard chemotherapy (platinum doublet chemotherapy or single-agent chemotherapy in selected patients)
  5. (ECOG) performance status 0-1.
  6. Patients must have a ≥ 12 weeks
  7. Females should be using adequate measures, should not be breast feeding and must have a negative pregnancy test prior to start of dosing if of or must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening:
  8. Male patients should be willing to use barrier contraception
  9. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
  10. At least one
  11. Provision of archival FFPE tissue
  12. Provision of informed consent for translational genetic research

Exclusion criteria

Exclusion Criteria:

  1. Involvement in the planning and/or conduct of the study (applies to both sponsor staff and/or staff at the study site)
  2. Previous treatment with osimertinib (3rd generation EGFR TKIs such as olumtinib, EGF816 etc)
  3. Treatment with an drug within five half-lives of the compound
  4. Patients currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be potent inhibitors of (at least 1 week prior) and potent inducers of CYP3A4 (at least 3 week prior) (Appendix A). All patients must try to avoid concomitant use of any medications, herbal supplements and/or ingestion of foods with known inducer/inhibitory effects on CYP3A4.
  5. Any unresolved toxicities from prior therapy greater than (CTCAE) grade 1 at the time of starting study treatment with the exception of alopecia and grade 2, prior platinum-therapy related neuropathy.
  6. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardise compliance with the protocol, or active infection including , and (HIV). Screening for chronic conditions is not required.
  7. Patients with symptomatic who are neurologically unstable; however, those with asymptomatic CNS metastases who do not require for at least 4 weeks prior to start of osimertinib are eligible.
  8. Past medical history of ILD, drug-induced ILD, radiation pneumonitis requiring steroid treatment, or any evidence of clinically active ILD
  9. Inadequate bone marrow reserve or organ function
  10. prolongation (mean resting corrected QTc > 470 msec)
  11. nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of osimertinib
  12. History of to osimertinib (or drugs with a similar chemical structure or class to osimertinib) or any of these agents
  13. Males and females of who are not using an effective method of and females who are pregnant or breastfeeding or have a positive (urine or serum) pregnancy test prior to study entry
  14. Judgment by the Investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements
  15. Previous bone marrow transplant.
  16. Non-leukocyte depleted whole blood transfusion within 120 days of the date of the genetic sample collection.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Osimertinib

    Osimertinib at 80mg dose will be administered orally once daily.

    Drug: Osimertinib 80 MG [Tagrisso]

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response Rate

    Investigator-assessed, confirmed objective response by RECIST version 1.1

    Time frame: Until study completion, from date of initiation until the date of first documented progression, unacceptable toxicities or withdrawl, whichever came first. (upto about 29months)

Secondary outcomes

  1. Serious Adverse Events

    AEs/SAEs as defined by NCI CTCAE version 4.0

    Time frame: From date of initiation until the date of first documented progression, unacceptable toxicities or withdrawal, whichever came first. Until study completion. (upto about 29months)

  2. Progression-free Survival

    PFS as defined by RECIST version 1.1

    Time frame: From date of initiation until the date of first documented progression, unacceptable toxicities or withdrawl, whichever came first. Until study completion. (upto about 29months)

  3. Overall Survival

    OS as defined by RECIST version 1.1. The time from the first date of IP administration to the date of death.

    Time frame: From the first date of IP administration to the date of death. (upto about 29months)

07

Results

Posted Feb 11, 2025

Participant flow

Participant flow — Overall Study
MilestoneOsimertinib
Started15
Completed15
Not completed0

Outcome measures

PrimaryObjective Response Rate

Investigator-assessed, confirmed objective response by RECIST version 1.1

Time frame:
Until study completion, from date of initiation until the date of first documented progression, unacceptable toxicities or withdrawl, whichever came first. (upto about 29months)
Reported as:
Count of participants · Participants
Objective Response Rate
ParticipantsOsimertinib
Objective Response Rate0
SecondarySerious Adverse Events

AEs/SAEs as defined by NCI CTCAE version 4.0

Time frame:
From date of initiation until the date of first documented progression, unacceptable toxicities or withdrawal, whichever came first. Until study completion. (upto about 29months)
Reported as:
Number · cases
Serious Adverse Events
casesOsimertinib
General weakness1
Acute urinary retention1
Pneumonia2
Colitis1
Azotemia1
Hypercalcemia1
Femur fracture1
SecondaryProgression-free Survival

PFS as defined by RECIST version 1.1

Time frame:
From date of initiation until the date of first documented progression, unacceptable toxicities or withdrawl, whichever came first. Until study completion. (upto about 29months)
Reported as:
Median · months
Progression-free Survival
monthsOsimertinib
Progression-free Survival3.8 (1.7 to 5.5)
SecondaryOverall Survival

OS as defined by RECIST version 1.1. The time from the first date of IP administration to the date of death.

Time frame:
From the first date of IP administration to the date of death. (upto about 29months)
Reported as:
Median · months
Overall Survival
monthsOsimertinib
Overall Survival6.5 (3.9 to 29)

Adverse events

Collected over from the day of first IP administration to 30 days after the last IP administration (till PD or unacceptable toxicity), (upto about 29months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Osimertinib2/15 (13.3%)8/15 (53.3%)15/15 (100%)
Most frequent serious events
Most frequent serious events
EventOsimertinib
PneumoniaRespiratory, thoracic and mediastinal disorders2/15
ColitisGastrointestinal disorders1/15
AzotemiaRenal and urinary disorders1/15
HyperglycemiaBlood and lymphatic system disorders1/15
General weaknessGeneral disorders1/15
Acute urinary retentionRenal and urinary disorders1/15
Femur fractureMusculoskeletal and connective tissue disorders1/15
Most frequent other events
Showing 10 of 19
Most frequent other events
EventOsimertinib
AnaemiaBlood and lymphatic system disorders4/15
DyspepsiaGastrointestinal disorders3/15
NauseaGastrointestinal disorders3/15
VomitingGastrointestinal disorders3/15
PyrexiaGeneral disorders3/15
DiarrhoeaGastrointestinal disorders2/15
Dry eyeEye disorders1/15
ThrombocytopeniaBlood and lymphatic system disorders1/15
ColitisGastrointestinal disorders1/15
ConstipationGastrointestinal disorders1/15

Baseline characteristics

Patients with NSCLC harboring EGFR exon 20 insertions

Age, Continuous
Age, Continuous(years)Osimertinib
Median61 (42 to 76)
Sex: Female, Male
Sex: Female, Male(Participants)Osimertinib
Female10
Male5
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Osimertinib
American Indian or Alaska Native0
Asian15
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Osimertinib
South Korea15
08

Study locations

1 site
  • Seoul National University Hospital
    Seoul, 110-744, Korea, Republic of
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Aug 2021, 42 months.

Results were first posted in Feb 2025, 3 years 6 months after primary completion.

Of 729 non-industry phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's 42 months is below that.

Counting every sponsor, half of 1,046 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2017
First posted
Jan 30, 2018
StartActual
Jan 4, 2018
Primary completionActual
Aug 3, 2021
CompletionActual
Aug 3, 2021
Results first posted
Feb 11, 2025
Last update
Feb 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03414814
Collaborators
AstraZeneca, Korean Cancer Study Group
Responsible party
Tae Min Kim (Associate Professor, Seoul National University Hospital) — Principal investigator
First posted
Jan 30, 2018
Start date
Jan 4, 2018
Primary completion
Aug 3, 2021
Completion
Aug 3, 2021
Results posted
Feb 11, 2025
Last update
Feb 11, 2025

Study contacts

Tae Min Kim, MD, PhD
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Osimertinib

Start the discussion